Haddox Candace L, Riedel Richard F
Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.
Duke Cancer Institute, Durham, NC, USA.
Fac Rev. 2021 Jan 4;10:1. doi: 10.12703/r/10-1. eCollection 2021.
Liposarcomas are a common subfamily of soft tissue sarcoma with several subtypes recognized by the World Health Organization: atypical lipomatous tumors (ALT)/well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS), pleomorphic liposarcoma (PLPS), and myxoid pleomorphic liposarcoma (MPLPS). Despite shared adipocytic features among liposarcomas, the clinical approach to each subtype differs based on histology, location, clinical behavior, and specific oncogenic drivers. In this review, we highlight subtype-specific molecular features with the potential to generate novel therapies. We discuss recent clinical trials investigating the use of preoperative radiation therapy for retroperitoneal liposarcoma, chemotherapy, small molecule inhibitors, and innovative immunotherapy approaches and describe how we incorporate these advancements into the management of liposarcoma.
脂肪肉瘤是软组织肉瘤中常见的一个亚类，世界卫生组织认可的有几种亚型：非典型脂肪瘤性肿瘤（ALT）/高分化脂肪肉瘤（WDLPS）、去分化脂肪肉瘤（DDLPS）、黏液样脂肪肉瘤（MLPS）、多形性脂肪肉瘤（PLPS）以及黏液样多形性脂肪肉瘤（MPLPS）。尽管脂肪肉瘤之间存在共同的脂肪细胞特征，但基于组织学、位置、临床行为和特定致癌驱动因素，针对每种亚型的临床治疗方法有所不同。在本综述中，我们重点介绍具有产生新疗法潜力的亚型特异性分子特征。我们讨论了最近关于术前放疗用于腹膜后脂肪肉瘤、化疗、小分子抑制剂以及创新免疫治疗方法的临床试验，并描述了我们如何将这些进展纳入脂肪肉瘤的管理中。
